Elsevier

Clinical Therapeutics

Volume 29, Issue 7, July 2007, Pages 1415-1420
Clinical Therapeutics

Absolute Bioavailability of Intranasal Fluticasone Furoate in Healthy Subjects

https://doi.org/10.1016/j.clinthera.2007.07.028Get rights and content

Abstract

Background: Fluticasone furoate (drug code GW685698) is an enhanced-affinity glucocorticoid that has been developed for the treatment of allergic rhinitis.

Objectives: The objectives of this study were to estimate the absolute bioavailability of fluticasone furoate nasal spray and to describe the intranasal (IN) and IV pharmacokinetics of fluticasone furoate in healthy subjects.

Methods: This was a single-center, randomized, open label, 2-period crossover study. Healthy male and female subjects were randomized to receive supra-therapeutic doses of fluticasone furoate 880 μg IN qSh for 10 doses in 1 treatment period, and a single IV dose of 250 pg fluticasone furoate given as an infusion over 20 minutes in the other treatment period. Each treatment period was separated by a 4- to 5-day washout period. Blood sampling was carried out over 8 hours following the final IN dose and 24 hours following the IV dose to determine plasma fluticasone furoate concentrations. Plasma samples were analyzed for fluticasone furoate using online solid-phase extraction with high-performance liquid chromatography with tandem mass-spectrometric detection. The lower limit of quantification was 10 pg/mL. The sample size was based primarily on logistical considerations. Sample-size sensitivity was assessed by estimating the 90% CI for the absolute bioavailability of IN fluticasone furoate, based on different estimated bioavailabilities and within-subject SDs. The following pharmacokinetic parameters were derived: IN administration: AUC from time 0 to the end of the dosing interval (AUC0−τ), AUC0−t, Cmax, and Tmax; IV administration: AUC0−∞, AUC0−t, t1/2, Cmax, Tmax, total systemic clearance, and volume of distribution at steady state.

Results: A total of 16 subjects were included in the study. Their mean age was 27.8 years (range, 19–45 years), and their mean body weight was 72.84 kg (range, 55.3–97.2 kg). The geometric mean AUC0−τ for 880 μg IN was 74.9 pg · mL/h and geometric mean AUC0−∞ for 250 μg IV was 4259 pg · mL/h. The geometric mean of the absolute bioavailability of fluticasone furoate nasal spray in these healthy subjects was 0.50% (90% CI, 0.34%–0.74%). The administration of large doses by the IN route did not elicit clinical concern. Three (19%) of 16 subjects reported adverse events (AEs) during the IN administration period, with 2 subjects experiencing dizziness and 1, toothache. Five (31%) subjects reported AEs during the IV administration period, with 3 subjects experiencing infusion-site or IV catheter-related events; 1 subject, dizziness; and 1 subject, headache.

Conclusions: The geometric mean of the absolute bioavailability of fluticasone furoate 880 μg IN qSh for 10 doses in these healthy subjects was low—0.50%.

References (10)

  • PT Daley-Yates et al.

    Relationship between systemic corticosteroid exposure and growth velocity: Development and validation of a pharmacokinetic/pharmacodynamic model

    Clin Ther

    (2004)
  • BJ Lipworth

    Systemic adverse effects of inhaled corticosteroid therapy: A systemic review and meta-analysis

    Arch Intern Med

    (1999)
  • PT Daley-Yates et al.

    Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays

    EurJ Clin Pharmacol

    (2004)
  • A Allen et al.

    Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects

    Ann Allergy Asthma Immunol.

    (2007)
  • J Upward

    A part-randomised, single dose, open label, 6-way cross-over study to assess the relative systemic pharmacokinetics and absolute bioavailability of 2 and 3 m GW685698X (2000 g), FTIM GW685698X material (2000 g) and FP (1000 g) administered via Diskhaler in healthy male subjects

    (2003)
There are more references available in the full text version of this article.

Cited by (53)

  • Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate: Pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate

    2022, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    Lower systemic bioavailability following inhalation has been reported for MF, but MF also has a greater number of metabolites including active metabolites [11,18,19]. In contrast, following administration as an aqueous nasal spray, all three molecules have similar bioavailability, pharmacokinetics (PK) and systemic pharmacodynamics (PD) [20,21]. A report of very low (<1%) systemic bioavailability following inhaled administration of MF may be as a consequence of the low single dose studied together with the relatively insensitive assay used to detect MF in plasma [14,22].

  • Same lung deposited dose in dog dosing a fine and coarse aerosol indicates no difference in intranasal filtration

    2022, International Journal of Pharmaceutics
    Citation Excerpt :

    Extremely low aqueous solubility is known to result in low oral bioavailability (Boyd et al., 2019) but it will also result in low nasal bioavailability, as shown for low solubility steroids such as fluticasone propionate (McDowall et al., 1997), fluticasone furoate (Allen et al., 2007) and mometasone furoate (Hochhaus, 2008). The absorption directly in the nose is limited by the poor solubility because the nasal mucosal contact time is limited (Allen et al., 2007) and most of the drug is therefore cleared by the nasal cilia and swallowed before dissolution occurs (Daley-Yates, 2001). The swallowed dose will however also be poorly absorbed orally due to the extremely low solubility and the contribution to the systemic exposure will therefore be negligible of the dose trapped by the intranasal filtration.

View all citing articles on Scopus
View full text